Apnimed is a late-stage pharmaceutical company developing Oxnimbi, an oral pill for obstructive sleep apnea (OSA). OSA is a chronic condition characterized by the repeated collapse of the upper airway during sleep. Oxnimbi combines aroxybutynin and atomoxetine into a once-nightly tablet designed to increase upper airway muscle activity and prevent collapse. This mechanism targets the neuromuscular root cause of the disease. Apnimed submitted an NDA to the FDA in April 2026 based on Phase 3 trials involving approximately 1,300 adults. Apnimed's business model focuses on the commercialization of branded prescription drugs, generating revenue through sales to patients with reimbursement from commercial and government insurers. The company is establishing a direct commercial infrastructure, including a sales force of 125-150 representatives targeting sleep specialists and primary care physicians. Apnimed is currently pre-revenue and funds operations through debt, private equity, and the sale of its interest in a joint venture with Shionogi. The company also maintains early-stage preclinical programs for other sleep-related breathing disorders. Key risks include the FDA's assessment of the clinical meaningfulness of trial results and the tolerability of the drug combination.